STOCK TITAN

Health Catalyst (NASDAQ: HCAT) holders back pay, auditor and retain classified board

(Moderate)
(Negative)
Form Type
8-K

Rhea-AI Filing Summary

Health Catalyst, Inc. held its annual stockholder meeting on July 16, 2026, with 73,894,020 shares entitled to vote and 54,417,854 shares present or represented by proxy. Stockholders elected Class I directors Justin Spencer and Mathew Arens for terms expiring at the 2029 annual meeting.

Stockholders ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved the advisory, non-binding vote on named executive officer compensation. They did not approve a proposal to restate the certificate of incorporation to phase out the classified board structure.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Shares Entitled to Vote 73,894,020 shares Common stock entitled to vote at the July 16, 2026 annual meeting
Shares Present or by Proxy 54,417,854 shares Common stock present or represented by valid proxy at the annual meeting
Votes for Justin Spencer 41,161,528 votes For election as Class I director at the 2026 annual meeting
Votes for Mathew Arens 40,617,062 votes For election as Class I director at the 2026 annual meeting
Votes for Auditor Ratification 54,389,755 votes Votes for ratifying Ernst & Young LLP as auditor for fiscal year 2026
Votes for Say-on-Pay 40,369,051 votes Votes for advisory, non-binding approval of executive compensation
Votes for Board Declassification Proposal 41,751,707 votes Votes for proposal to phase out the classified board structure
broker non-votes regulatory
"Votes For | Votes Against | Abstentions | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
advisory, non-binding regulatory
"The stockholders approved the advisory, non-binding proposal to approve"
classified board structure regulatory
"to phase out the classified board structure and provide that all directors"
A classified board structure divides a company’s board of directors into separate groups (or “classes”) with staggered, multi-year terms so that only a portion of directors is up for election each year. It matters to investors because it makes replacing the entire board quickly difficult—like trying to swap out only a few players on a team each season—offering protection against hostile takeovers and short-term disruption but potentially reducing board accountability and slowing strategic change.
Amended and Restated Certificate of Incorporation regulatory
"To Approve the Restatement of the Company's Amended and Restated Certificate of Incorporation"
A company’s amended and restated certificate of incorporation is an updated version of its foundational legal charter that replaces the older document and folds in all changes into one clear copy; it spells out corporate structure, classes of stock, shareholder rights and key governance rules. Investors care because it can change who controls the company, how votes are counted, what claims shareholders have on assets or dividends, and can introduce or remove protections against takeovers—like updating a house title after a major renovation to show who owns what and under what rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Health Catalyst (HCAT) stockholders vote on at the July 16, 2026 annual meeting?

Stockholders voted on four proposals: electing two Class I directors, ratifying Ernst & Young LLP as auditor, approving advisory executive compensation, and approving a restatement to phase out the company’s classified board structure starting with directors elected at the 2029 annual meeting.

How many Health Catalyst (HCAT) shares were represented at the 2026 annual meeting?

A total of 73,894,020 shares of common stock were entitled to vote, and 54,417,854 shares were present or represented by valid proxy, establishing a voting base for all four proposals considered at the annual meeting.

Were Health Catalyst (HCAT) director nominees elected at the 2026 annual meeting?

Yes. Class I director nominees Justin Spencer and Mathew Arens were elected. Spencer received 41,161,528 votes for and Arens received 40,617,062 votes for, each with broker non-votes of 12,330,154, to serve terms expiring at the 2029 annual meeting.

Did Health Catalyst (HCAT) stockholders approve executive compensation in 2026?

Yes. Stockholders approved the advisory, non-binding vote on compensation for named executive officers, with 40,369,051 votes for, 992,493 against, 726,156 abstentions, and 12,330,154 broker non-votes recorded on this say-on-pay proposal.

What happened to Health Catalyst (HCAT)’s proposal to phase out its classified board structure?

Stockholders did not approve the proposal to restate the Amended and Restated Certificate of Incorporation to phase out the classified board structure. The vote was 41,751,707 for, 335,034 against, 959 abstentions, and 12,330,154 broker non-votes on this governance change.

Which audit firm did Health Catalyst (HCAT) stockholders ratify for the 2026 fiscal year?

Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 54,389,755 votes for, 26,050 votes against, and 2,049 abstentions recorded on this ratification proposal.
FALSE000163642200016364222026-07-162026-07-160001636422dei:FormerAddressMember2026-07-162026-07-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________________________________
FORM 8-K
__________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 16, 2026
__________________________________________________________
HEALTH CATALYST, INC.
(Exact name of registrant as specified in its charter)
________________________________________________________________
Delaware001-3899345-3337483
(State or other jurisdiction of
incorporation)
(Commission File Number)(IRS Employer
Identification No.)
10897 South River Front Parkway #300
South Jordan, UT 84095
(Address of principal executive offices, including zip code)

(801) 708-6800
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)
______________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 
     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
______________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of exchange on which registered
Common Stock, par value $0.001 per shareHCATThe Nasdaq Global Select Market
________________________________________________________
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ((§240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.








Item 5.07. Submission of Matters to a Vote of Security Holders.

On July 16, 2026, Health Catalyst, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). The Company’s stockholders voted on four proposals at the Annual Meeting, each of which is described in greater detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on June 3, 2026. The number of shares of the Company's common stock entitled to vote at the Annual Meeting was 73,894,020. The number of shares of the Company’s common stock present or represented by valid proxy at the Annual Meeting was 54,417,854. The final voting results with respect to each such proposal are set forth below.

Proposal 1 – Election of Directors
The Company’s stockholders elected each of the two persons named below to serve as a Class I director of the Company to serve a three-year term expiring at the 2029 annual meeting of the stockholders or until their successors are duly elected and qualified, subject to their earlier resignation or removal. The results of such vote were as follows:

Director Name
Votes For
Votes Withheld
Broker Non-Votes
Justin Spencer41,161,528926,17212,330,154
Mathew Arens40,617,0621,470,63812,330,154


Proposal 2 – Ratification of the Appointment of the Company’s Independent Registered Public Accounting Firm
The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of such vote were as follows:

Votes ForVotes AgainstAbstentions
54,389,75526,0502,049


Proposal 3 – Advisory, Non-Binding Vote to Approve the Compensation of the Company’s Named Executive Officers
The stockholders approved the advisory, non-binding proposal to approve the compensation of the Company’s named executive officers. The results of such vote were as follows:
Votes For
Votes Against
AbstentionsBroker Non-Votes
40,369,051992,493726,15612,330,154

Proposal 4 – To Approve the Restatement of the Company's Amended and Restated Certificate of Incorporation to Phase Out the Classified Board Structure
The stockholders did not approve the proposal to restate the Company's Amended and Restated Certificate of Incorporation to phase out the classified board structure and provide that all directors elected at or after the Company's 2029 annual meeting of stockholders be elected on an annual basis. The results of such vote were as follows:
Votes For
Votes Against
AbstentionsBroker Non-Votes
41,751,707335,03495912,330,154





SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HEALTH CATALYST, INC.
Date: July 17, 2026By:/s/ Jason Alger
Jason Alger
Chief Financial Officer


Filing Exhibits & Attachments

4 documents